A Phase 1 interventional study of Selinexor and Acetaminophen in Solid Tumor, sponsored by Karyopharm Therapeutics Inc. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Karyopharm Therapeutics Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 330 studies in Carcinoma, Squamous Cell with a site in United States — 68 open to participants now, 99 under way, 6 of them phase 3. Carcinoma, Squamous Cell · United States.
Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, this one is the 45th largest by enrollment of the 280 interventional ones that give a count, is one of 11 that started in 2012, is one of 80 in phase 1, and was the 111th registered.
629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.
Browse Carcinoma, Squamous Cell studies →68 of the 330 studies in Carcinoma, Squamous Cell with a site in United States are open now. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Rockefeller University · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
330 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 108 · Phase 2 138 · Phase 3 28 · Phase 4 4
First in 1994; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 45 across 478 interventional studies indexed under Carcinoma, Squamous Cell.
Median enrollment 37 across the 280 interventional studies, 64 across the 45 observational. Of the 203 that completed or were terminated, 94 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 330 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 2 studies filed under Carcinoma, Squamous Cell — fewer than ten, so there is no comparison to draw.
31 of the studies in Carcinoma, Squamous Cell with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07931664The Center for Clinical and Cosmetic ResearchEvaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | 2026-11 |
| NCT06615635Alpha Tau Medical LTD.Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients | 2026-12 |
| NCT05863052University of OklahomaAnalyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | 2026-12-31 |
| NCT05366166UNC Lineberger Comprehensive Cancer CenterPembrolizumab Plus Olaparib in LA-HNSCC | 2027-01-21 |
Add all 31 to your calendar (.ics) → With an account.
Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
This is a phase 1a and phase 1b, open-label, dose-escalation study to evaluate the safety and tolerability of selinexor and determine the RP2D in patients with solid tumor malignancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Dose Escalation Phase: Patients with advanced or solid tumors for which no standard therapy is available. For Schedule 6 only: patients with colorectal cancer with liver metastasis.
Dose Expansion Phase: Previously treated, metastatic or advanced recurrent with 1 of the following diagnoses, which has been confirmed histologically or cytologically:
Up to 12 patients with incurable Squamous cell cancers as follows:
Both Dose Escalation and Expansion Phases: There is no upper limit on the number of prior treatments provided that all inclusion criteria are met and exclusion criteria are not met. Hormone ablation therapy is considered an anticancer regimen. Radiation and surgery are not considered anticancer regimes.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with colorectal cancer and liver metastasis received oral selinexor as single agent in 8 schedules, Schedule1: ≤12milligrams per meter square(mg/m\^2) 3 times weekly(TIW) during Weeks 1 and 3, twice weekly(BIW) during Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule2: \>12mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule3: ≥30mg/m\^2 BIW(Days 1 and 3) up to 8 doses/cycle(28 days/cycle); Schedule4: ≥20mg/m\^2 BIW(Days 1 and 2) up to 8 doses/cycle(28 days/cycle); Schedule5: ≥35mg/m\^2 BIW(Days 1 and 4) up to 8 doses(28 days/cycle); Schedule6: ≥20mg/m\^2 BIW(Days 1 and 4) after 500 mg(Week 1) to 1000 mg(Week 2 onwards) acetaminophen(given 1 hour prior to each selinexor dose) up to 8 doses/cycle (28 days/cycle); Schedule7: ≥50mg/m\^2 once weekly(QW) up to 4 doses/cycle(28 days per cycle); Schedule8: ≥45mg/m\^2 BIW(Days 1 and 3) up to 4 doses/cycle(21 days/cycle), until disease progression, death, or unacceptable toxicity.
Drug: Selinexor · Drug: Acetaminophen
Participants with gynecological cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
Drug: Selinexor
Participants with squamous cell cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
Drug: Selinexor
Participants with castrate-resistant prostate cancer (CRPC) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
Drug: Selinexor
Participants with glioblastoma multiforme (GBM) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
Drug: Selinexor
Participants with Melanoma received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
Drug: Selinexor
Participants with other solid tumors received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
Drug: Selinexor
Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
Also known as: KPT-330, XPOVIO
Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria; is fatal, life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events. Number of participants with TEAEs and TESAEs were reported.
Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)
Number of Participants With Treatment-related Treatment-emergent Adverse Events
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product; the event had a causal relationship with the treatment or usage.
Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. A treatment related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage.
Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)
Number of Participants Who Experienced Dose Limiting Toxicity (DLT)
Evaluation of DLTs was only conducted in participants who participated in the Dose-escalation Phase. A DLT was defined as any of the following, considered possibly related to drug administration, occurring in the first 28 days (or 21 days for participants on Schedule 8) at the target dose (ie, for Schedule 2 this meant the first 4 weeks after the 12 mg/m2 run-in week): Missed selinexor doses due to drug-related toxicities, discontinuation of a participant due to a toxicity that was at least possibly related to study drug before completing Cycle 1.
Time frame: Cycle 1 only (28-day cycle)
Recommended Phase 2 Dose (RP2D)
The RP2D was the maximum tolerated dose (MTD) or less. MTD was defined as the next lower dose level below the one in which \>1 of 3 participants or ≥2 of 6 participants experienced DLT, provided that dose level was ≤25 percent (%) lower than the highest (intolerable) dose tested. If the projected MTD was \>25% lower than the highest dose tested, then an additional cohort of ≥3 participants was added at a dose that was intermediate between the intolerable dose and the next lower dose.
Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)
Maximum Observed Plasma Concentration (Cmax) of Selinexor
Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.
Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Time of Maximum Observed Concentration in Plasma (Tmax) of Selinexor
Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.
Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Area Under the Concentration Time Curve From the Time of Dosing to Time in Plasma (AUC0-t) of Selinexor
AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.
Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Area Under the Concentration Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Selinexor
AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated). It was calculated as AUC0-t + Ct/kel, where: Ct = the last observed non-zero concentration and Kel = elimination rate constant.
Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Elimination Half-Life (t1/2) of Selinexor
t1/2 was defined as elimination half-life, it was calculated as ln(2)/kel, where In = natural logarithm and kel = elimination rate constant.
Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Apparent Total Body Clearance (CL/F) of Selinexor
CL/F was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).
Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Apparent Volume of Distribution of Selinexor (Vd/F)
Vd/F was calculated as Dose/(kel \* AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).
Time frame: Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes
Number of Participants With Best Overall Response (BOR)
BOR is response recorded from start of treatment until disease progression/recurrence. Best lesion response was defined by Recist Criteria V1 (for target and non-target lesions) and RANO criteria (for glioblastoma multiforme): complete response (CR)- disappearance of all target lesions. Any pathological lymph nodes (target/non target) must have reduction in short axis to less than (\<) 10 mm; partial response (PR)- at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum longest diameter; stable disease (SD)- steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; progressive disease (PD): at least 20% increase in sum of diameters of measured lesions taking as references smallest sum of diameters recorded since treatment started. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm, or appearance of one or more new lesions.
Time frame: Up to maximum duration of 45 months
Percentage of Participants With Objective Response
Objective response rate (ORR) was determined as percentage of participants who had either CR or PR, as defined by RECIST v1.1 (for solid tumors). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (target/non target) must have reduction in short axis to \<10 mm and PR was defined as at least 30% decrease in sum of diameters of target lesions. ORR was calculated as a proportion and included a 2 sided 95% CI using the exact (Clopper-Pearson) method.
Time frame: Up to maximum duration of 45 months
Duration of Stable Disease (SD)
Duration of stable disease was defined as the time from the date of first dose to first documented radiologic evidence of disease recurrence or progression, as defined by RECIST v1.1 (for solid tumors) or RANO criteria (for GBM and AnaA).
Time frame: From first dose of study drug administration to first documented evidence of disease recurrence or progression (maximum duration of 45 months)
Progression-free Survival (PFS)
Progression-free survival was calculated from the date of first dose of study treatment to first documented evidence of disease recurrence or progression or death due to any cause. Patients who are last known to be alive and without evidence of progression will be censored at time of last evaluable disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, patients are censored at the time of last evaluable disease assessment prior to the missed assessment. Progressive disease was defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of one or more new lesions also constituted progressive disease.
Time frame: From start of study drug administration until PD or discontinuation from the study or death (maximum duration of 45 months)
Overall Survival (OS)
OS was calculated from the date of first dose to date of death. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropout prior to study end, were censored at the day they were last known to be alive. The OS was calculated using the Kaplan-Meier method.
Time frame: From first dose of study drug administration to date of death (maximum duration of 45 months)
The study was conducted at six centers in United States, Canada, and Denmark from 18 June 2012 and 15 March 2016.
| Milestone | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Started | 60 | 20 | 21 | 21 | 7 | 15 | 47 |
| Received study drug | 59 | 20 | 21 | 21 | 6 | 15 | 47 |
| Low dose (<30 mg/m^2) | 16 | 5 | 3 | 0 | 0 | 2 | 8 |
| Medium dose (>=30 mg/m^2 and <55 mg/m^2) | 27 | 11 | 15 | 8 | 6 | 3 | 21 |
| High dose (>= 55 mg/m^2) | 16 | 4 | 3 | 13 | 0 | 10 | 18 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 60 | 20 | 21 | 21 | 7 | 15 | 47 |
| Withdrew: Withdrawal by participant | 7 | 2 | 4 | 6 | 0 | 4 | 12 |
| Withdrew: Incidence or severity of aes | 5 | 1 | 1 | 3 | 0 | 2 | 8 |
| Withdrew: Disease progression | 44 | 16 | 15 | 11 | 6 | 7 | 21 |
| Withdrew: Non-compliance with study procedures | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 1 | 1 | 1 | 1 | 0 | 0 | 3 |
| Withdrew: Other treatments become available | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Investigator discretion | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 | 0 | 1 | 1 | 0 |
An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria; is fatal, life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events. Number of participants with TEAEs and TESAEs were reported.
| Participants | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Participants with TEAEs | 59 | 20 | 21 | 21 | 6 | 15 | 46 |
| Participants with TESAEs | 30 | 13 | 9 | 8 | 2 | 5 | 24 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product; the event had a causal relationship with the treatment or usage.
| Participants | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Participants with Treatment-related TEAEs | 59 | 19 | 20 | 21 | 6 | 14 | 45 |
| Participants with Treatment-related TESAEs | 6 | 2 | 1 | 4 | 1 | 1 | 9 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. A treatment related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage.
| Participants | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03 | 50 | 17 | 16 | 17 | 4 | 11 | 35 |
Evaluation of DLTs was only conducted in participants who participated in the Dose-escalation Phase. A DLT was defined as any of the following, considered possibly related to drug administration, occurring in the first 28 days (or 21 days for participants on Schedule 8) at the target dose (ie, for Schedule 2 this meant the first 4 weeks after the 12 mg/m2 run-in week): Missed selinexor doses due to drug-related toxicities, discontinuation of a participant due to a toxicity that was at least possibly related to study drug before completing Cycle 1.
| Participants | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced Dose Limiting Toxicity (DLT) | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
The RP2D was the maximum tolerated dose (MTD) or less. MTD was defined as the next lower dose level below the one in which \>1 of 3 participants or ≥2 of 6 participants experienced DLT, provided that dose level was ≤25 percent (%) lower than the highest (intolerable) dose tested. If the projected MTD was \>25% lower than the highest dose tested, then an additional cohort of ≥3 participants was added at a dose that was intermediate between the intolerable dose and the next lower dose.
| mg/m^2 | Arms A to G: Overall Solid Tumor Malignancies |
|---|---|
| Recommended Phase 2 Dose (RP2D) | 35 |
Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.
| nanogram per milliliter | Selinexor Dose: 3 mg/m^2 | Selinexor Dose: 6 mg/m^2 | Selinexor Dose: 12 mg/m^2 | Selinexor Dose: 16.8 mg/m^2 | Selinexor Dose: 20 mg/m^2 | Selinexor Dose: 23 mg/m^2 | Selinexor Dose: 28 mg/m^2 | Selinexor Dose: 30 mg/m^2 | Selinexor Dose: 35 mg/m^2 | Selinexor Dose: 39 mg/m^2 | Selinexor Dose: 40 mg/m^2 | Selinexor Dose: 45 mg/m^2 | Selinexor Dose: 50 mg/m^2 | Selinexor Dose: 55 mg/m^2 | Selinexor Dose: 58 mg/m^2 | Selinexor Dose: 65 mg/m^2 | Selinexor Dose: 70 mg/m^2 | Selinexor Dose: 80 mg/m^2 | Selinexor Dose: 85 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Selinexor | 30 | 75 ± 38.2 | 149 ± 32 | 168 | 220 ± 44.5 | 308 ± 12.1 | 293 ± 58.3 | 413 ± 46.7 | 349 ± 25.4 | 528 ± 12.5 | 442 ± 63.6 | 390 ± 25.3 | 507 ± 57.8 | 505 ± 18.2 | 561 ± 45.4 | 896 ± 71.7 | 521 | 765 ± 6.6 | 1371 ± 31.1 |
Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.
| hours | Selinexor Dose: 3 mg/m^2 | Selinexor Dose: 6 mg/m^2 | Selinexor Dose: 12 mg/m^2 | Selinexor Dose: 16.8 mg/m^2 | Selinexor Dose: 20 mg/m^2 | Selinexor Dose: 23 mg/m^2 | Selinexor Dose: 28 mg/m^2 | Selinexor Dose: 30 mg/m^2 | Selinexor Dose: 35 mg/m^2 | Selinexor Dose: 39 mg/m^2 | Selinexor Dose: 40 mg/m^2 | Selinexor Dose: 45 mg/m^2 | Selinexor Dose: 50 mg/m^2 | Selinexor Dose: 55 mg/m^2 | Selinexor Dose: 58 mg/m^2 | Selinexor Dose: 65 mg/m^2 | Selinexor Dose: 70 mg/m^2 | Selinexor Dose: 80 mg/m^2 | Selinexor Dose: 85 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time of Maximum Observed Concentration in Plasma (Tmax) of Selinexor | 1 | 2.1 (0.9 to 7.5) | 2.0 (1.0 to 7.7) | 2.1 | 2.3 (2.0 to 7.5) | 2.1 (1.1 to 8.0) | 3.1 (0.5 to 7.6) | 2.9 (0.5 to 7.7) | 3.8 (2.0 to 7.8) | 3.1 (1.0 to 4.3) | 3.9 (2.1 to 4.2) | 4.2 (2.1 to 8.0) | 3.0 (1.0 to 4.1) | 3.8 (1.1 to 4.0) | 3.1 (2.2 to 4.2) | 2.0 (0.6 to 7.5) | 8.0 | 3.9 (3.8 to 4.0) | 3.9 (3.8 to 3.9) |
AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.
| nanogram hour per milliliter | Selinexor Dose: 3 mg/m^2 | Selinexor Dose: 6 mg/m^2 | Selinexor Dose: 12 mg/m^2 | Selinexor Dose: 16.8 mg/m^2 | Selinexor Dose: 20 mg/m^2 | Selinexor Dose: 23 mg/m^2 | Selinexor Dose: 28 mg/m^2 | Selinexor Dose: 30 mg/m^2 | Selinexor Dose: 35 mg/m^2 | Selinexor Dose: 39 mg/m^2 | Selinexor Dose: 40 mg/m^2 | Selinexor Dose: 45 mg/m^2 | Selinexor Dose: 50 mg/m^2 | Selinexor Dose: 55 mg/m^2 | Selinexor Dose: 58 mg/m^2 | Selinexor Dose: 65 mg/m^2 | Selinexor Dose: 70 mg/m^2 | Selinexor Dose: 80 mg/m^2 | Selinexor Dose: 85 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration Time Curve From the Time of Dosing to Time in Plasma (AUC0-t) of Selinexor | 333 | 707 ± 13.6 | 1578 ± 21.0 | 1369 | 2446 ± 23.3 | 3387 ± 17.7 | 3106 ± 31 | 3861 ± 16.6 | 3691 ± 25.0 | 4885 ± 15.3 | 5255 ± 24.4 | 4390 ± 24.9 | 5490 ± 3.1 | 5803 ± 23.5 | 5888 ± 18.9 | 8482 ± 44.8 | 7210 | 9838 ± 12.7 | 11485 ± 20.1 |
AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated). It was calculated as AUC0-t + Ct/kel, where: Ct = the last observed non-zero concentration and Kel = elimination rate constant.
| nanogram hour per milliliter | Selinexor Dose: 3 mg/m^2 | Selinexor Dose: 6 mg/m^2 | Selinexor Dose: 12 mg/m^2 | Selinexor Dose: 16.8 mg/m^2 | Selinexor Dose: 20 mg/m^2 | Selinexor Dose: 23 mg/m^2 | Selinexor Dose: 28 mg/m^2 | Selinexor Dose: 30 mg/m^2 | Selinexor Dose: 35 mg/m^2 | Selinexor Dose: 39 mg/m^2 | Selinexor Dose: 40 mg/m^2 | Selinexor Dose: 45 mg/m^2 | Selinexor Dose: 50 mg/m^2 | Selinexor Dose: 55 mg/m^2 | Selinexor Dose: 58 mg/m^2 | Selinexor Dose: 65 mg/m^2 | Selinexor Dose: 70 mg/m^2 | Selinexor Dose: 80 mg/m^2 | Selinexor Dose: 85 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Selinexor | 355 | 808 ± 5.2 | 1613 ± 21.4 | 1455 | 2269 ± 27.2 | 3332 ± 17.3 | 3936 | 3961 ± 12.1 | 4585 ± 18.2 | 5014 ± 18.0 | 5294 ± 24.0 | 3395 | 5688 ± 0.6 | 5894 ± 24.8 | 6567 ± 12.8 | 10265 ± 31.4 | — | 9025 | 11830 ± 20.1 |
t1/2 was defined as elimination half-life, it was calculated as ln(2)/kel, where In = natural logarithm and kel = elimination rate constant.
| hours | Selinexor Dose: 3 mg/m^2 | Selinexor Dose: 6 mg/m^2 | Selinexor Dose: 12 mg/m^2 | Selinexor Dose: 16.8 mg/m^2 | Selinexor Dose: 20 mg/m^2 | Selinexor Dose: 23 mg/m^2 | Selinexor Dose: 28 mg/m^2 | Selinexor Dose: 30 mg/m^2 | Selinexor Dose: 35 mg/m^2 | Selinexor Dose: 39 mg/m^2 | Selinexor Dose: 40 mg/m^2 | Selinexor Dose: 45 mg/m^2 | Selinexor Dose: 50 mg/m^2 | Selinexor Dose: 55 mg/m^2 | Selinexor Dose: 58 mg/m^2 | Selinexor Dose: 65 mg/m^2 | Selinexor Dose: 70 mg/m^2 | Selinexor Dose: 80 mg/m^2 | Selinexor Dose: 85 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elimination Half-Life (t1/2) of Selinexor | 6.2 | 5.6 (4.8 to 6.4) | 5.0 (4.1 to 7.8) | 5.7 | 5.6 (4.2 to 7.5) | 5.8 (5.7 to 6.4) | 5.7 | 6.5 (4.1 to 7.9) | 6.0 (4.0 to 7.0) | 5.9 (3.5 to 6.2) | 6.9 (5.4 to 7.2) | 7.3 | 7.3 (7.1 to 7.5) | 6.2 (5.0 to 10.1) | 6.5 (5.6 to 7.1) | 6.9 (5.5 to 9.3) | — | 5.7 | 5.3 (4.6 to 6.0) |
CL/F was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).
| liter per hour per kilogram | Selinexor Dose: 3 mg/m^2 | Selinexor Dose: 6 mg/m^2 | Selinexor Dose: 12 mg/m^2 | Selinexor Dose: 16.8 mg/m^2 | Selinexor Dose: 20 mg/m^2 | Selinexor Dose: 23 mg/m^2 | Selinexor Dose: 28 mg/m^2 | Selinexor Dose: 30 mg/m^2 | Selinexor Dose: 35 mg/m^2 | Selinexor Dose: 39 mg/m^2 | Selinexor Dose: 40 mg/m^2 | Selinexor Dose: 45 mg/m^2 | Selinexor Dose: 50 mg/m^2 | Selinexor Dose: 55 mg/m^2 | Selinexor Dose: 58 mg/m^2 | Selinexor Dose: 65 mg/m^2 | Selinexor Dose: 70 mg/m^2 | Selinexor Dose: 80 mg/m^2 | Selinexor Dose: 85 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Total Body Clearance (CL/F) of Selinexor | 0.20 | 0.18 ± 7.9 | 0.19 ± 16 | 0.20 | 0.19 ± 27 | 0.19 ± 26.1 | 0.18 | 0.17 ± 16.8 | 0.20 ± 26.7 | 0.20 ± 12.5 | 0.19 ± 24.4 | 0.27 | 0.18 ± 10.6 | 0.20 ± 17.1 | 0.20 ± 17.0 | 0.15 ± 32.7 | — | 0.22 | 0.18 ± 4.1 |
Vd/F was calculated as Dose/(kel \* AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).
| liter per kilogram | Selinexor Dose: 3 Milligram Per Square Meter (mg/m2) | Selinexor Dose: 6 mg/m2 | Selinexor Dose: 12 mg/m2 | Selinexor Dose: 16.8 mg/m2 | Selinexor Dose: 20 mg/m2 | Selinexor Dose: 23 mg/m2 | Selinexor Dose: 28 mg/m2 | Selinexor Dose: 30 mg/m2 | Selinexor Dose: 35 mg/m2 | Selinexor Dose: 39 mg/m2 | Selinexor Dose: 40 mg/m2 | Selinexor Dose: 45 mg/m2 | Selinexor Dose: 50 mg/m2 | Selinexor Dose: 55 mg/m2 | Selinexor Dose: 58 mg/m2 | Selinexor Dose: 65 mg/m2 | Selinexor Dose: 70 mg/m2 | Selinexor Dose: 80 mg/m2 | Selinexor Dose: 85 mg/m2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution of Selinexor (Vd/F) | 1.8 | 1.4 ± 12.5 | 1.4 ± 22.5 | 1.6 | 1.6 ± 20.9 | 1.6 ± 21.2 | 1.5 | 1.6 ± 6.6 | 1.6 ± 26.6 | 1.5 ± 26.1 | 1.9 ± 31.1 | 2.8 | 1.9 ± 14.3 | 1.9 ± 24.7 | 1.8 ± 15.4 | 1.5 ± 31.8 | — | 1.8 | 1.4 ± 22.7 |
BOR is response recorded from start of treatment until disease progression/recurrence. Best lesion response was defined by Recist Criteria V1 (for target and non-target lesions) and RANO criteria (for glioblastoma multiforme): complete response (CR)- disappearance of all target lesions. Any pathological lymph nodes (target/non target) must have reduction in short axis to less than (\<) 10 mm; partial response (PR)- at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum longest diameter; stable disease (SD)- steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; progressive disease (PD): at least 20% increase in sum of diameters of measured lesions taking as references smallest sum of diameters recorded since treatment started. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm, or appearance of one or more new lesions.
| Participants | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Partial Response | 1 | 3 | 0 | 0 | 0 | 1 | 1 |
| Stable Disease | 15 | 9 | 5 | 11 | 0 | 3 | 20 |
| Progression (Objective) | 28 | 6 | 8 | 5 | 5 | 4 | 10 |
| Progressive Disease due to symptomatic deterioration | 4 | 0 | 3 | 0 | 0 | 1 | 1 |
| Not Evaluable | 9 | 2 | 5 | 3 | 1 | 4 | 14 |
Objective response rate (ORR) was determined as percentage of participants who had either CR or PR, as defined by RECIST v1.1 (for solid tumors). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (target/non target) must have reduction in short axis to \<10 mm and PR was defined as at least 30% decrease in sum of diameters of target lesions. ORR was calculated as a proportion and included a 2 sided 95% CI using the exact (Clopper-Pearson) method.
| percentage of participants | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response | 1.8 | 15.0 | 0 | 0 | 0 | 14.3 | 2.2 |
Duration of stable disease was defined as the time from the date of first dose to first documented radiologic evidence of disease recurrence or progression, as defined by RECIST v1.1 (for solid tumors) or RANO criteria (for GBM and AnaA).
| Days | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Duration of Stable Disease (SD) | 53 (52 to 59) | 119 (42 to 310) | 52 (46 to 79) | 133 (53 to 484) | 43 (38 to 55) | 52 (22 to 539) | 134 (53 to 267) |
Progression-free survival was calculated from the date of first dose of study treatment to first documented evidence of disease recurrence or progression or death due to any cause. Patients who are last known to be alive and without evidence of progression will be censored at time of last evaluable disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, patients are censored at the time of last evaluable disease assessment prior to the missed assessment. Progressive disease was defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of one or more new lesions also constituted progressive disease.
| Days | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | 53 (52 to 59) | 119 (42 to 310) | 52 (44 to 79) | 127 (53 to 322) | 41 (38 to 55) | 52 (22 to 539) | 88 (53 to 234) |
OS was calculated from the date of first dose to date of death. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropout prior to study end, were censored at the day they were last known to be alive. The OS was calculated using the Kaplan-Meier method.
| Days | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 136 (102 to 532) | 491 (167 to NA) | 161 (62 to 460) | 354 (322 to NA) | 103 (38 to 152) | NA (125 to NA) | 290 (263 to NA) |
Collected over From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (Colorectal Cancer) | — | 30/59 (50.8%) | 59/59 (100%) |
| Arm B (Gynecological Cancer) | — | 13/20 (65%) | 20/20 (100%) |
| Arm C (Squamous Cell Cancer) | — | 9/21 (42.9%) | 21/21 (100%) |
| Arm D (Castrate-resistant Prostate Cancer) | — | 8/21 (38.1%) | 21/21 (100%) |
| Arm E (Glioblastoma Multiforme) | — | 2/6 (33.3%) | 6/6 (100%) |
| Arm F (Melanoma) | — | 5/15 (33.3%) | 15/15 (100%) |
| Arm G (Other Solid Tumors) | — | 24/47 (51.1%) | 46/47 (97.9%) |
| Event | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/59 | 0/20 | 0/21 | 0/21 | 1/6 | 0/15 | 2/47 |
| AnaemiaBlood and lymphatic system disorders | 0/59 | 0/20 | 0/21 | 1/21 | 1/6 | 0/15 | 0/47 |
| Lung infectionInfections and infestations | 2/59 | 2/20 | 1/21 | 0/21 | 1/6 | 0/15 | 2/47 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/59 | 0/20 | 0/21 | 0/21 | 1/6 | 0/15 | 0/47 |
| LethargyNervous system disorders | 0/59 | 0/20 | 0/21 | 0/21 | 1/6 | 0/15 | 0/47 |
| EmbolismVascular disorders | 0/59 | 1/20 | 0/21 | 1/21 | 1/6 | 0/15 | 0/47 |
| Small intestinal obstructionGastrointestinal disorders | 1/59 | 3/20 | 0/21 | 0/21 | 0/6 | 0/15 | 0/47 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/59 | 0/20 | 0/21 | 0/21 | 0/6 | 2/15 | 2/47 |
| Large intestinal obstructionGastrointestinal disorders | 1/59 | 2/20 | 1/21 | 0/21 | 0/6 | 0/15 | 0/47 |
| FatigueGeneral disorders | 2/59 | 2/20 | 0/21 | 0/21 | 0/6 | 0/15 | 1/47 |
| Event | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 46/59 | 19/20 | 12/21 | 9/21 | 3/6 | 11/15 | 38/47 |
| VomitingGastrointestinal disorders | 35/59 | 17/20 | 11/21 | 7/21 | 2/6 | 5/15 | 27/47 |
| FatigueGeneral disorders | 46/59 | 16/20 | 14/21 | 17/21 | 5/6 | 10/15 | 36/47 |
| Decreased appetiteMetabolism and nutrition disorders | 42/59 | 13/20 | 11/21 | 14/21 | 5/6 | 9/15 | 33/47 |
| Weight decreasedInvestigations | 32/59 | 8/20 | 11/21 | 10/21 | 4/6 | 7/15 | 19/47 |
| AnaemiaBlood and lymphatic system disorders | 23/59 | 13/20 | 13/21 | 10/21 | 3/6 | 4/15 | 21/47 |
| HyponatraemiaMetabolism and nutrition disorders | 36/59 | 8/20 | 7/21 | 6/21 | 1/6 | 9/15 | 17/47 |
| ThrombocytopeniaBlood and lymphatic system disorders | 26/59 | 6/20 | 9/21 | 12/21 | 3/6 | 8/15 | 23/47 |
| DiarrhoeaGastrointestinal disorders | 24/59 | 11/20 | 8/21 | 7/21 | 1/6 | 7/15 | 16/47 |
| ConstipationGastrointestinal disorders | 21/59 | 9/20 | 6/21 | 11/21 | 1/6 | 5/15 | 22/47 |
Safety Population included all participants who received at least one dose of selinexor. As pre-specified in the study Protocol data were not collected per dose level. The limited data available based on cancer stratification as pre-specified in the protocol is presented.
| Age, Continuous(years) | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 59.8 ± 11.35 | 55.0 ± 12.54 | 59.2 ± 7.39 | 68.7 ± 7.69 | 56.0 ± 14.94 | 67.7 ± 11.04 | 57.7 ± 12.67 | 60.2 ± 11.82 |
| Sex: Female, Male(Participants) | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 25 | 20 | 9 | 0 | 3 | 4 | 14 | 75 |
| Male | 34 | 0 | 12 | 21 | 3 | 11 | 33 | 114 |
| Race (NIH/OMB)(Participants) | Arm A (Colorectal Cancer) | Arm B (Gynecological Cancer) | Arm C (Squamous Cell Cancer) | Arm D (Castrate-resistant Prostate Cancer) | Arm E (Glioblastoma Multiforme) | Arm F (Melanoma) | Arm G (Other Solid Tumors) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 0 | 4 | 2 | 0 | 1 | 5 | 22 |
| White | 45 | 18 | 17 | 16 | 6 | 14 | 41 | 157 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
Plan to share: Yes
Ran from Jun 2012 to primary completion in Mar 2016, 44 months.
Results were first posted in Apr 2021, 5 years 1 month after primary completion.
Of 45 phase 1 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 62. This study's 44 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor